D
emographics may play an important role in a patient's clinical response to antihypertensive therapy. [1] [2] [3] [4] [5] For example, calcium antagonists have been shown to be more efficacious in the treatment of hypertension in older African American patients compared to angiotensin-converting enzyme inhibitors; diuretics may be less effective in younger white patients than in younger African American patients with hypertension. 1 However, the influence of such individual characteristics on response to treatment is not routinely evaluated in clinical hypertension trials.
This may be particularly true with respect to the patient characteristics of gender and age. It is generally believed that response to antihypertensive therapy is equivalent in men and women and in older and younger patients, and that treatment thus need not be individualized based on these characteristics. However, responses to antihypertensive therapy among men and women and among older and younger patients have shown conflicting results. [2] [3] [4] [5] [6] Complicating this issue is the fact that clinical trials with antihypertensives generally are not designed to detect or to account for potential differences among various subpopulations. 7 In fact, several of the early, larger trials studying antihypertensive therapies did not even include women in the study population. 8 -10 Controlled-onset, extended-release (COER-24) verapamil is a novel formulation of this calcium channel blocker [11] [12] [13] that has been shown to have significant pharmacokinetic differences in men and women after steadystate dosing. 14 Additionally, in older subjects, the plasma concentration of the S-enantiomer of verapamil is increased compared to that in a younger, gender-matched population.
14 Thus, this agent could potentially have differences in both pharmacodynamic and adverse clinical effects in hypertensive men and women and in older and younger hypertensive patients. For these reasons, we studied the clinical effects of COER-verapamil in patient subgroups using 24-h ambulatory monitoring of the blood pressure (BP) and heart rate in placebo-controlled trials.
Methods

Study Design
Data were pooled from three prospective North American, multicenter, double-blind, randomized, placebo-controlled, parallel-group clinical trials evaluating the efficacy BP ϭ blood pressure; other abbreviation as in Table 1 .
and tolerability of COER-verapamil in patients with stage I to III hypertension. All three trials included a 1-to 2-week washout period followed by a 2-to 4-week, singleblind placebo phase to establish baseline hemodynamic values. Patients then were randomized to 8 weeks of double-blind treatment with either COER-verapamil (180 to 540 mg) or placebo. Doses were administered once daily at 10 PM because of the chronotherapeutic delivery system of the drug. 11, 12 Noninvasive ambulatory BP monitoring was used in all trials to assess the change from baseline in BP, heart rate, and the heart rate-systolic blood pressure product (rate-pressure product).
Study Population
At the end of the single-blind placebo phase, men and women between the ages of 21 and 79 years with an average seated diastolic BP of 95 to 115 mm Hg on 2 consecutive weeks as measured by mercury sphygmomanometry (both readings within 8 mm Hg of each other), as well as a mean daytime ambulatory diastolic BP Ͼ90 mm Hg were randomized to double-blind treatment. Efficacy and tolerability data collected during these trials were stratified based on the following patient characteristics: age Ͻ60 versus Ն60 years, and men versus women. Studies had been approved by each investigator's institutional review board, and informed consent was obtained from every patient before any study procedure.
Patients were excluded from the trials if they had known secondary hypertension, coronary artery disease, congestive heart failure, high-grade cardiac conduction abnormalities (including atrioventricular block), sick sinus syndrome, alcoholism, psychosis, serious chronic medical diseases (eg, hepatic or renal insufficiency), or malabsorption syndromes. Patients who worked exclusively at night or worked various shifts throughout a 24-h period also were excluded.
Clinic and Ambulatory Blood Pressure Measurements
Clinic BP was measured by mercury column sphygmomanometry in duplicate in seated and standing positions at all visits. Heart rate was measured in duplicate in conjunction with each BP measurement for a minimum of 30 sec. Ambulatory BP monitoring (Spacelabs model 90202, Redmond, WA) was used to assess the change from baseline in BP and heart rate. Patients underwent ambulatory monitoring for 24 h, with measurements taken every 15 min, at the end of the single-blind placebo period (baseline) and after the completion of double-blind study drug (treatment). For purposes of chronotherapeutic analyses, [11] [12] [13] ambulatory measurements were divided into four time intervals: early morning (6 AM to 10 AM), daytime (8 AM to 8 PM), nighttime (8 PM to 8 AM), and 24-h (mean). For ambulatory measurements to be included in the analysis, at least 80% of the readings in the 24-h postdose period must have been valid, including a minimum of two valid read-
FIG. 1.
Impact of gender: changes from baseline in ambulatory blood pressure, heart rate, and rate-pressure product after COER-verapamil therapy. COER-verapamil ϭ controlled-onset, extended-release verapamil; BP ϭ blood pressure.
ings per hour during the first 20 h and a minimum of three valid readings per hour during at least 3 of the last 4 h. The latter criterion was due to a particular interest in the assessment of the early morning changes in BP and heart rate. 11, [15] [16] [17] If measurements failed to meet these criteria, patients were asked to repeat the study within 2 days. Patients whose ambulatory BP monitoring studies failed to meet the above criteria were considered nonevaluable. Patients included in the final efficacy analysis were those who had evaluable clinic and ambulatory BP readings at the end of the placebo baseline phase and at the end of double-blind treatment.
Data Analyses
The primary efficacy variables were defined as the changes from baseline in mean systolic and diastolic BP, heart rate, and the rate-pressure product measured during the 24-h monitoring period among the placebo and COER-verapamil treatment groups. Statistical comparisons of these efficacy measurements for COER-verapamil versus placebo were performed using two-tailed t tests. To compare the efficacy parameters in men versus women and older versus younger patients, analyses of covariance that included baseline BP, heart rate, or rate-pressure product, as well as dose of COER-verapamil, age, or gender (depending on the analysis) were performed.
The tolerability and safety of COER-verapamil was assessed by monitoring the incidence of adverse events in treated patients compared with those on placebo. Adverse events were defined as new clinical abnormalities reported after treatment with the study drug that either were not reported during the placebo baseline or were reported during baseline but worsened in severity during doubleblind treatment. Tolerability data were collected for patients who received at least one dose of study drug (intentto-treat analysis). The incidence of adverse events was compared among treatment groups and in the various subgroups using two-tailed Fisher exact tests.
Results
Study Patient Characteristics
Ambulatory BP and heart rate data at baseline and following completion of the double-blind treatment phase were available for a total of 398 patients (128 older patients v 270 younger patients; 272 men v 126 women). In all, 68% of the entire study population was comprised of younger patients; men accounted for 68% of the study population. Safety and tolerability data were compiled from a total of 441 patients (299 younger patients v 142 older patients, 297 men v 144 women) who received at least one dose of study medication. There were no significant differences in baseline characteristics between placebo and COER-verapamil-treated patients (Tables 1 and 2 ).
Efficacy of COER-Verapamil in Men and Women
The mean age of patients treated with COER-verapamil was 54 Ϯ 10 years in the male patients and 52 Ϯ 10 years in the female patients (P ϭ NS). Ethnic characteristics, body mass index (29.9 kg/m 2 for men and 29.3 kg/m 2 for women), mean doses of COER-verapamil (373 mg/day for men and 377 mg/day for women), and baseline hemodynamic values (Table 2 ) also were similar.
Mean changes in the ambulatory BP, heart rate, and rate-pressure product values for men and women treated with COER-verapamil are shown in Fig. 1 . In both men and women, the largest reductions in ambulatory BP after COER-verapamil occurred during the early-morning interval. Final 24-h BP levels achieved after 8 weeks of treatment with COER-verapamil were 141/86 mm Hg in the men and 137/83 mm Hg in the women. Women treated with COER-verapamil achieved significantly greater reductions in systolic and diastolic BP throughout the 24-h period compared with COER-verapamil-treated men (Fig.  2) . Although women also tended to have greater reductions in heart rate and the rate-pressure product when compared to men (Fig. 1) , these changes from baseline between the two genders were not statistically significant (with the exception of nighttime rate-pressure product, P Ͻ .05, data not shown).
Efficacy of COER-Verapamil in Older and Younger Patients
The mean age in the older patient group was 65 Ϯ 4 years and in the younger patient group was 48 Ϯ 7 years. Other characteristics of the older and younger patients treated with COER-verapamil were similar. The majority of patients in both age groups were male (75.5% in the older group v 67.5% in the younger group); the ethnic distribution was similar, and mean body mass indexes were comparable (28.4 kg/m 2 in the older group v 30.4 kg/m 2 in the younger group). The mean dose of COER-verapamil at the end of double-blind treatment was 382.4 mg/day for the younger patients v 355.9 mg/day for older patients (P ϭ NS). The analyses of efficacy accounted for differences in baseline ambulatory BP and heart rate values, as the older population tended to demonstrate higher systolic BP on placebo compared with younger patients (Table 2) .
Changes from baseline in the ambulatory BP, heart rate, and rate-pressure product in older and younger patients treated with COER-verapamil are shown in Fig. 3 . Older patients showed larger reductions in 24-h diastolic BP and 24-h and early-morning heart rate (Fig. 3) . These differences in the response to treatment with COER-verapamil between older and younger patients remained significant after adjusting for body mass index and dose of COERverapamil. At the end of the double-blind treatment period, the mean 24-h BP in patients treated with COERverapamil was 138/86 Ϯ 12/8 mm Hg in younger patients and 143/84 Ϯ 14/8 mm Hg in older patients. Although older patients experienced greater decreases in heart rate compared with younger patients, with a corresponding trend toward lower rate-pressure products, the incidence of first-degree heart block was not significantly greater in the older patients and, in fact, was similar to placebo in both age groups (2.1% in older patients v 1.5% in younger patients; P ϭ .653). No patient in any group had secondor third-degree atrioventricular block.
Changes from baseline in the 24-h BP and heart rate profiles comparing older and younger patient groups on COER-verapamil are shown in Fig. 4 . The changes in the BP and heart rate were the least during the nighttime period while effects of the drug were greatest during the early-morning period.
Clinic Blood Pressure and Heart Rate
Changes in the clinic BP measured by mercury sphygmomanometry and heart rate results showed patterns similar to those obtained with ambulatory monitoring (Tables 3  and 4) . Women showed larger changes in clinic BP than did men, during both early morning and trough evening hours (Table 3) . Similarly, older patients treated with COER-verapamil generally demonstrated larger decreases from baseline than did younger patients during both the peak-and trough-effect periods of COER-verapamil (Table 4). These trends were similar to those observed with the primary ambulatory BP monitoring analyses.
Comparisons of Safety and Tolerability According to Gender and Age
The adverse events that were reported with an incidence exceeding 5% in men versus women and in older versus younger patients are shown in Table 5 . The most frequently reported adverse effect among all COER-verapamil-treated subpopulations was constipation. None of these adverse events were statistically more frequent in women versus men or in the older versus the younger patients.
Discussion
The principal findings of our study demonstrated that antihypertensive treatment with COER-verapamil yielded greater reductions in ambulatory BP in women compared with men and greater reductions in ambulatory diastolic BP and heart rate in older versus younger patients with hypertension. These findings were shown persistently throughout the 24-h dosing, with the largest reductions in BP and heart rate during the early-morning interval. Lesser (but significant) reductions in BP, heart rate, and the rate-pressure product were achieved throughout the daytime and nighttime intervals. Treatment with COER-verapamil was well tolerated in all subgroups, with constipa- Abbreviations as in Tables 1 and 2 . Table 4 . Changes from baseline in clinic blood pressure, heart rate, and rate-pressure product, by age Abbreviations as in Tables 1-3 .
tion the most frequently reported adverse effect and the only adverse effect to occur at a significantly higher incidence than with placebo. Previous clinical trials have demonstrated the general efficacy and tolerability of COER-verapamil in the treatment of patients with stage I to III hypertension. [11] [12] [13] 17 In the present study, analyses were expanded to include the effects of age (Ͻ60 v Ն60 years) and gender on the 24-h ambulatory BP, heart rate, and rate-pressure product responses to treatment with the drug. Older patients had greater reductions in diastolic BP, heart rate, and the rate pressure product compared to younger patients throughout the entire dosing interval. Similarly, with the exception of early-morning and daytime heart rate, women demonstrated a greater response to treatment compared with men. It is well established that the effects of COERverapamil are dose-dependent in the general hypertensive population 11, 13 ; thus, in all of these analyses, an effort was made to assure that these findings were not confounded by average doses in the various subgroups, differences in body mass index, or baseline hemodynamic variables.
Comparisons With Other Studies
Differences in the effects of the calcium channel blocker amlodipine have been reported in men versus women by Kloner et al. 4 This community-based study evaluated the effects of amlodipine on clinic BP in 1084 men and women with mild to moderate hypertension. Treatment with amlodipine resulted in small but significantly greater BP reductions in women compared with men (average gender difference of 2.5/1.1 mm Hg, P Ͻ .05). In older patients, BP fell 4.5/2.2 mm Hg greater compared with that in younger patients, which was highly significant (P Ͻ .0001) after accounting for changes in baseline values and mg/kg dose. Similar to our analyses, the difference in response by age was independent of the difference in response by gender. In the gender analyses, however, the amlodipine dose was higher in men compared with women (0.114 mg/kg v 0.097 mg/kg; P Ͻ .0001) and may have resulted in greater effects in men. In older versus younger patients, there was no difference in dose normalized for weight. No other factors were readily identified that could account for the difference in BP response among the subpopulations.
Other trials with calcium channel blockers have shown certain differences between ambulatory and clinic measurements of BP and heart rate based on sex. In a study by Loeb et al, 18 it was revealed that women demonstrated a larger "white coat effect" or pressor response in the clinic environment compared to that in men. After a 1-week placebo phase, women demonstrated a much higher clinic systolic BP than ambulatory systolic BP, whereas men demonstrated relatively similar clinic and ambulatory measurements. After 4 weeks of treatment with either nifedipine or verapamil, women demonstrated a significantly greater reduction in clinic systolic BP than did men (P Ͻ .005), whereas reductions in ambulatory systolic BP were the same for both sexes. Thus, in that study, a large "white coat effect" in women accounted for most of the gender differences in clinic BP response to calcium antagonists. A study by Krakoff et al 19 also demonstrated a larger clinic systolic BP reduction in women compared with men in response to similar doses of the calcium channel blocker nifedipine GITS, although similar proportions of men and women achieved BP control values.
Impact of Gender and Age on the Pharmacodynamics of COER-Verapamil
Gender and age characteristics may affect the pharmacokinetics of drugs because of alterations in the absorption, distribution, or elimination of drugs. 20 Of key relevance in older patients is an increased volume of distribution of drugs associated with reductions in lean body mass, cardiac output, serum albumin, or reduced drug elimination due to changes in hepatic and renal blood flow. 20 Similarly, these pharmacokinetic differences may occur between women and men; however, the data are less clear than for the age effects. 21 Age and gender differences in the pharmacokinetics of COER-verapamil have been reported by Gupta et al. 14 In that study, 60 volunteers received 180 mg of COERverapamil at bedtime on 5 consecutive days to achieve pharmacologic steady state. In older patients (65 to 80 years), there was a significant 1.5-fold increase in the maximal concentration of both the S-and R-enantiomers of verapamil compared to that in younger patients (19 to 43 years; P Ͻ .05). Similarly, the area under the concentration curve (AUC 0 -24 ) in older patients was approximately twice as great as the AUC for younger patients. There were no significant differences in the time required to achieve maximal concentrations of the drug for the older and younger groups. In the analysis of the impact of gender on verapamil pharmacokinetics, plasma concentrations of verapamil and AUC values at steady state were significantly higher in the women compared with men, independent of age. Thus, these pharmacokinetic findings are in concert with the efficacy data shown in the present study, whereby similar doses of COER-verapamil achieved greater 24-h ambulatory BP and heart rate effects in older patients and in women ( Fig. 1 and 3) . In summary, we have found clinically relevant differences in changes in ambulatory BP and heart rate that are attributable to gender and age with the calcium antagonist COER-verapamil. Although age typically is taken into consideration during drug development due to safety concerns, most clinical trials with antihypertensive agents have not taken into consideration the potential effects of gender on efficacy or tolerability. Whether these pharmacokinetic and pharmacodynamic differences might affect cardiovascular outcomes with antihypertensive therapy is one of the many hypotheses being assessed in the Controlled Onset Verapamil Investigation for Cardiovascular Endpoints (CONVINCE) trial. 22 Further evaluation of differences in response to treatment between men and women and between older and younger patients may help to identify whether specific antihypertensive regimens may offer therapeutic advantages in these populations.
